Jeroen Jansen, PhD

Associate Professor

Department of Clinical Pharmacy

[email protected]

490 Illinois Street, Rm 32M

UCSF Box 0613

San Francisco, CA 94158

United States

Links

UCSF Profiles

Affiliations

What I do

I am a member of the Center for Translational and Policy Research on Precision Medicine (TRANSPERS). I work on applied and methods research to understand the clinical and economic value of drugs and other health technologies.

Departmental research area

clinical research

health services and policy research

My research expertise

evidence synthesis, meta-analysis, network meta-analysis, comparative effectiveness, health economics, cost-effectiveness analysis, decision-modeling, health technology assessment, precision medicine, epidemiology, Bayesian statistics

Professional background

Biography

Jeroen is a methodologist working at the intersection of evidence synthesis, biostatistics, and health economics. He is a core faculty member with the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), located in the Department of Clinical Pharmacy.

Jeroen has worked on research to understand the clinical and economic value of healthcare interventions. His research has frequently been conducted in the context of health technology assessment (HTA), with a focus on comparative effectiveness and cost-effectiveness. Prompted by the challenges encountered in applied research projects, Jeroen has performed methodological research. Notable contributions are the development of novel statistical methods to overcome the typical challenges in model-based cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. Furthermore, Jeroen led initiatives to develop guidance for consumers and producers of network meta-analysis studies. He has promoted a more transparent and credible approach to model-based health economic evaluations and led the development of open-source simulation models to illustrate its feasibility. Jeroen has been involved in the ongoing development of an R software package to develop simulation models for health economic evaluations.

Jeroen’s current research interests are the clinical and economic value of precision medicine, incorporating health disparities in health economic modeling studies, and statistical methods for evidence synthesis.

Research keywords

health technology assessment
Bayesian statistics
health economics
decision-modeling
cost-effectiveness analysis
comparative effectiveness
health disparities
precision medicine
network meta-analysis
evidence synthesis
Cost-Benefit Analysis
Carcinoma, Non-Small-Cell Lung
network meta-analysis
Randomized Controlled Trials as Topic
Models, Economic
Indans
Meta-Analysis as Topic
Antirheumatic Agents
Quality-Adjusted Life Years
Diphosphonates
Quinolones
Arthritis, Rheumatoid
Amphotericin B
Models, Statistical
Bronchodilator Agents

News

Publications

Park JE, Campbell H, Towle K, Yuan Y, Jansen JP, Phillippo D, Cope S. Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data. Value Health. 2024 Mar; 27(3):278-286.

Jansen JP, Brewer IP, Chung S, Sullivan P, Espinosa OD, Grossman JP. The Health Inequality Impact of a New Cancer Therapy Given Treatment and Disease Characteristics. Value Health. 2024 Feb; 27(2):143-152.

Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. medRxiv. 2023 Oct 28.

Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis. Value Health. 2023 Dec; 26(12):1697-1710.

Jansen JP, Incerti D, Trikalinos TA. Multi-state network meta-analysis of progression and survival data. Stat Med. 2023 08 30; 42(19):3371-3391.

Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. J Comp Eff Res. 2023 05; 12(5):e220098.

Cope S, Chan K, Campbell H, Chen J, Borrill J, May JR, Malcolm W, Branchoux S, Kupas K, Jansen JP. A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma. Value Health. 2023 04; 26(4):465-476.

Oluwole OO, Chen JMH, Chan K, Patel AR, Jansen JP, Keeping S, Zheng Y, Snider JT, Locke FL. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2022 Sep 01; 1-11.

Thom H, Leahy J, Jansen JP. Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. Med Decis Making. 2022 10; 42(7):906-922.

Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics. 2022 05; 40(5):489-495.

Hong YD, Jansen JP, Guerino J, Berger ML, Crown W, Goettsch WG, Mullins CD, Willke RJ, Orsini LS. Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Med. 2021 12 06; 19(1):307.

Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2021 10; 62(10):2482-2491.

Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R. . Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clinical Kidney Journal. 2021; 4(14):1136-46.

Jones KM, Cook-Deegan R, Rotimi CN, Callier SL, Bentley AR, Stevens H, Phillips KA, Jansen JP, Weyant CF, Roberts DE, Zielinski D, Erlich Y, Garrison NA, Carroll SR, Ossorio PN, Moreau Y, Wang M. Complicated legacies: The human genome at 20. Science. 2021 02 05; 371(6529):564-569.

Popoff E, Besada M, Jansen JP, Cope S, Kanters S. Aligning text mining and machine learning algorithms with best practices for study selection in systematic literature reviews. Syst Rev. 2020 Dec 13; 9(1):293.

Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. J Comp Eff Res. 2020 12; 9(18):1275-1284.

Incerti D, Hernandez EJM, Tkacz J, Jansen JP, Collier D, Gharaibeh M, Moore-Schiltz L, Stolshek BS. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis. J Manag Care Spec Pharm. 2020 Oct; 26(10):1236-1242.

Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma". Biol Blood Marrow Transplant. 2020 12; 26(12):e335-e336.

Thom H, Jansen J, Shafrin J, Zhao L, Joseph G, Cheng HY, Gupta S, Shah N. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. BMJ Open. 2020 09 17; 10(9):e034147.

Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ, Leusch MS, Muehlenbein CE, Li L, Jen MH, Rojubally A, Jansen J, Druyts E. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. Cancer Treat Res Commun. 2020; 24:100200.

Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2020 09; 26(9):1581-1588.

Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R, Desnick RJ. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clin Kidney J. 2021 Apr; 14(4):1136-1146.

Jansen JP. Heterogeneity and subgroup analysis in network meta-analysis. In: Ting N, Cappelleri J, Ho S, Chen G. (editors). Design and analysis of subgroups with biopharmaceutical applications. Emerging topics in statistics and biostatistics. Springer, Cham. 2020; 369-385.

Cope S, Chan K, Jansen JP. Multivariate network meta-analysis of survival function parameters. Res Synth Methods. 2020 May; 11(3):443-456.

Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value Health. 2020 04; 23(4):441-450.

Sussell J, Silverstein AR, Goutam P, Incerti D, Kee R, Chen CX, Batty DS, Jansen JP, Kasiske BL. The economic burden of kidney graft failure in the United States. Am J Transplant. 2020 05; 20(5):1323-1333.

Jansen JP, Incerti D, Linthicum MT. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project. Pharmacoeconomics. 2019 11; 37(11):1313-1320.

Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. Adv Ther. 2019 11; 36(11):2982-2985.

Cope S, Ayers D, Zhang J, Batt K, Jansen JP. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019 09 02; 19(1):182.

Cope S, Keeping ST, Goldgrub R, Ayers D, Jansen JP, Penrod JR, Korytowsky B, Juarez-Garcia A, Yuan Y. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer. J Comp Eff Res. 2019 07; 8(10):733-751.

Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. J Neurol. 2019 Sep; 266(9):2312-2321.

Incerti D, Curtis JR, Shafrin J, Lakdawalla DN, Jansen JP. A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. Pharmacoeconomics. 2019 06; 37(6):829-843.

Garrison LP, Jansen JP, Devlin NJ, Griffin S. Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework. Value Health. 2019 06; 22(6S):S12-S17.

Incerti D, Thom H, Baio G, Jansen JP. R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment. Value Health. 2019 05; 22(5):575-579.

Jansen JP, Incerti D, Curtis JR. Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System. J Manag Care Spec Pharm. 2019 May; 25(5):518-521.

Leahy J, Thom H, Jansen JP, Gray E, O'Leary A, White A, Walsh C. Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact. Stat Med. 2019 06 30; 38(14):2505-2523.

Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Adv Ther. 2019 05; 36(5):1164-1176.

Jansen JP, Khalid JM, Smyth MD, Patel H. The number needed to treat and relevant between-trial comparisons of competing interventions. Clinicoecon Outcomes Res. 2018; 10:865-871.

Lorenzi M, Ambegaonkar B, Baxter CA, Jansen J, Zoratti MJ, Davies G. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clin Res Cardiol. 2019 May; 108(5):487-509.

Shafrin J, Skornicki M, Brauer M, Villeneuve J, Lees M, Hertel N, Penrod JR, Jansen J. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? Health Policy. 2018 06; 122(6):607-613.

Ericsson Å, Glah D, Lorenzi M, Jansen JP, Fridhammar A. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLoS One. 2018; 13(2):e0191953.

Dias S, Ades AE. Welton N, Jansen JP, Sutton A.. Network Meta‐Analysis for Decision Making. 2018.

Evans M, Billings LK, Håkan-Bloch J, Slothuus U, Abrahamsen TJ, Andersen A, Jansen JP. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. J Med Econ. 2018 Apr; 21(4):340-347.

Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017 Jul; 20(7):703-714.

Jansen JP. Relevance of American Society of Clinical Oncology Value Framework Will Be Improved if It Is Based on Network Meta-Analyses. J Clin Oncol. 2017 04 01; 35(10):1131-1132.

Toth PP, Danese M, Villa G, Qian Y, Beaubrun A, Lira A, Jansen JP. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017 Jun; 20(6):555-564.

Druyts E, Palmer JB, Balijepalli C, Chan K, Fazeli MS, Herrera V, Jansen JP, Park JJH, Kanters S, Reimold A. Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):681-688.

Lorenzi M, Ploug UJ, Langer J, Skovgaard R, Zoratti M, Jansen J. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis. Diabetes Ther. 2017 Feb; 8(1):85-99.

Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clin Ther. 2016 Dec; 38(12):2628-2641.e5.

Jansen JP, Vieira MC, Bradley JD, Cappelleri JC, Zwillich SH, Wallenstein GV. Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016 08 18; 17(1):348.

Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017 Apr; 264(4):621-630.

Broekhuizen H, Groothuis-Oudshoorn CG, Hauber AB, Jansen JP, IJzerman MJ. Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis. BMC Med Inform Decis Mak. 2015 Dec 02; 15:102.

Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E. Erratum to: A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly. Infect Dis Ther. 2015 Dec; 4(4):489-90.

Szabo SM, Hedegaard M, Chan K, Thorlund K, Christensen R, Vorum H, Jansen JP. Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. Curr Med Res Opin. 2015 Nov; 31(11):2031-42.

Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly. Infect Dis Ther. 2015 Dec; 4(4):459-87.

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 02; 162(11):777-84.

Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. J Manag Care Spec Pharm. 2015 May; 21(5):409-23.

Jansen JP, Vieira MC, Cope S. Network meta-analysis of longitudinal data using fractional polynomials. Stat Med. 2015 Jul 10; 34(15):2294-311.

Toor K, Druyts E, Jansen JP, Thorlund K. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. J Med Econ. 2015 Jun; 18(6):437-46.

Cope S, Clemens A, Hammès F, Noack H, Jansen JP. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials. Value Health. 2015 Mar; 18(2):234-49.

Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to diagnose lung cancer. JAMA. 2015 Jan 27; 313(4):419.

Thorlund K, Druyts E, Toor K, Jansen JP, Mills EJ. Incorporating alternative design clinical trials in network meta-analyses. Clin Epidemiol. 2015; 7:29-35.

Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, Ball GD, Busse JW, Thorlund K, Guyatt G, Jansen JP, Mills EJ. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014 Sep 03; 312(9):923-33.

Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014 Jul 03; 12:102.

Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014 Jun 05; 12:93.

Ellis AG, Reginster JY, Luo X, Cappelleri JC, Chines A, Sutradhar S, Jansen JP. Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. Value Health. 2014 Jun; 17(4):424-32.

Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Curr Med Res Opin. 2014 Aug; 30(8):1617-26.

Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, Salanti G. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014 Mar; 17(2):157-73.

Cope S, Jansen JP. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol. 2013 Dec 01; 13:147.

Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013 Oct 07; 14:100.

Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2014 Apr; 47(4):772-785.e5.

Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013 Jul 04; 11:159.

Cope S, Ouwens MJ, Jansen JP, Schmid P. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health. 2013 Mar-Apr; 16(2):403-17.

Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012 Oct 08; 12:152.

Dequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist. 2012; 17(11):1376-85.

Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012; 7:415-20.

Cope S, Zhang J, Williams J, Jansen JP. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med. 2012 Jun 25; 12:29.

Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J Cyst Fibros. 2012 Sep; 11(5):419-26.

Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE. Economic outcomes of treatment for ureteral and renal stones: a systematic literature review. J Urol. 2012 Aug; 188(2):449-54.

Franchini AJ, Dias S, Ades AE, Jansen JP, Welton NJ. Accounting for correlation in network meta-analysis with multi-arm trials. Res Synth Methods. 2012 Jun; 3(2):142-60.

Jansen JP. Network meta-analysis of individual and aggregate level data. Res Synth Methods. 2012 Jun; 3(2):177-90.

Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE. Treatment of ureteral and renal stones: a systematic review and meta-analysis of randomized, controlled trials. J Urol. 2012 Jul; 188(1):130-7.

Jansen JP, Schmid CH, Salanti G. Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. J Clin Epidemiol. 2012 Jul; 65(7):798-807.

Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health. 2012 May; 15(3):524-33.

Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012; 6:6-20.

Ghosh S, Chandran A, Jansen JP. Epidemiology of HIV-related neuropathy: a systematic literature review. AIDS Res Hum Retroviruses. 2012 Jan; 28(1):36-48.

Vieira MC, Kumar RN, Jansen JP. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison. HIV Clin Trials. 2011 Jul-Aug; 12(4):175-89.

Jansen JP, Taylor SD. Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway. Int J Rheumatol. 2011; 2011:160326.

Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2011; 6:329-44.

Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011 Jun; 14(4):429-37.

Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011 Jun; 14(4):417-28.

Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011 May 06; 11:61.

Ouwens MJ, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods. 2010 Jul; 1(3-4):258-71.

Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011 Mar-Apr; 14(2):274-81.

Naik S, Lundberg J, Kumar R, Sjolin J, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand J Infect Dis. 2011 Jul; 43(6-7):504-14.

van de Kerkhof P, de Peuter R, Ryttov J, Jansen JP. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin. 2011 Jan; 27(1):225-38.

Fleurence RL, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood). 2010 Oct; 29(10):1826-33.

Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011 Feb; 40(4):275-84.e1-2.

Jansen JP, O'Sullivan AK, Lugtenburg E, Span LF, Janssen JJ, Stam WB. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann Hematol. 2010 Sep; 89(9):919-26.

Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010 Jun; 39(6):425-41.

Jansen JP, Gaugris S, Choy EH, Ostor A, Nash JT, Stam W. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics. 2010; 28(4):323-44.

Vissers DCJ, Nolte T, Stam WB, Lenre M, Jansen J. . Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010; 5(26):1037-45.

Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2009 Oct; 31(10):1255-62.

Jansen JP, Bergman GJ, Huels J, Olson M. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin. 2009 Aug; 25(8):1861-8.

Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health. 2009 Mar-Apr; 12(2):234-44.

Jansen JP, Kumar R, Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics. 2009; 27(12):1045-56.

Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008 Dec; 81(6):467-74.

Stam WB, Aversa F, Kumar RN, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health. 2008 Sep-Oct; 11(5):830-41.

Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008 Sep-Oct; 11(5):956-64.

Jansen JP, Gaugris S, Bergman G, Sen SS. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. Curr Med Res Opin. 2008 Mar; 24(3):671-84.

Jansen JP, Pellissier J, Choy EH, Ostor A, Nash JT, Bacon P, Hunsche E. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. Curr Med Res Opin. 2007 Dec; 23(12):3069-78.

Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007 Jun; 78(6):532-9.

Burdorf A, Jansen JP. Predicting the long term course of low back pain and its consequences for sickness absence and associated work disability. Occup Environ Med. 2006 Aug; 63(8):522-9.

Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006 Apr; 22(4):671-81.

Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health. 2006 Jan-Feb; 9(1):12-23.

Eriksen HR, Ihlebaek C, Jansen JP, Burdorf A. The relations between psychosocial factors at work and health status among workers in home care organizations. Int J Behav Med. 2006; 13(3):183-92.

Jansen JP, Meis JF, Blijlevens NM, van't Wout JW. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin. 2005 Oct; 21(10):1535-46.

Jansen JP, Morgenstern H, Burdorf A. Dose-response relations between occupational exposures to physical and psychosocial factors and the risk of low back pain. Occup Environ Med. 2004 Dec; 61(12):972-9.

Jansen JP, Burdorf A. Effects of measurement strategy and statistical analysis on dose-response relations between physical workload and low back pain. Occup Environ Med. 2003 Dec; 60(12):942-7.

Jansen JP, Burdorf A. Exposure assessment and its effect on the associations of physical load and back disorders. Arch Public Health. 2002; (60):153-72.

Jansen JP, Burdorf A, Steyerberg E. A novel approach for evaluating level, frequency and duration of lumbar posture simultaneously during work. Scand J Work Environ Health. 2001 Dec; 27(6):373-80.